Loss of heterozygosity (LOH) co-deletion 1p/19q, MGMT promoter methylation and/or IDH1 mutation generally signify a better prognosis for patients with glioma. However, the influence of 1p/19q co-deletion and the LOH on other chromosomes in primary glioblastoma on survival is still debatable. The aim of our study was to identify LOH on chromosomes 1p, 19q, 9p, 10q, 13q, and 17p, and evaluate their impact either alone or 1p/19q co-deletion or by groups of LOH on the overall survival of 42 primary glioblastoma patients without an oligodendroglial component. These patients were additionally molecularly characterized for EGFR amplification, IDH1 mutations and TP53 mutations. We assessed their influence on the overall survival of glioblastoma patients. LOH in at least one of the loci on all examined chromosomes was detected in 65% of cases and was significantly associated with shorter overall survival (hazard ratio 3.07; 95% CI: 1.29-7.31, p = 0.006). 1p/19q co-deletion was infrequent (7.14%) and had no impact on overall survival. Our results indicate that in primary glioblastoma a specific LOH group analysis may be important for the prognosis. LOH 1p/19q co-deletion is rare in glioblastoma without an oligodendroglial component and has no impact on patient survival.
Introduction
Glioblastoma (GB) carries complex genetic alterations resulting in a different molecular and epidemiological profile. In primary glioblastoma, the most common molecular alterations are LOH 10q (over 70%), EGFR amplification (about 40%), MDM2 amplification, LOH 10p and 10q, p16 INK4a and PTEN mutation. In secondary glioblastoma, the first common molecular event in multistep carcinogenesis is the mutation of IDH1, TP53, and LOH on 17p, 10q and 19q [1] [2] [3] .
There are three molecular markers related to better outcome of gliomas: MGMT promoter methylation is associated with a stronger benefit of radiochemotherapy in glioblastomas; IDH1 mutations are a strong and independent predictor of survival in both low-grade and high-grade gliomas; while 1p/19q co-deletion strongly predicts prolonged response to treatment and longer survival in oligodendroglial tumors [3] [4] [5] [6] . However, recent data showed that the prognostic significance of these markers should be used with caution [7] .
MGMT promoter methylation has been associated with better survival in glioblastoma treated with radiotherapy and alkylating agents [6] . In our previous study, MGMT promoter methylation had no prognostic value in glioblastoma patients who were treated only with surgery and radiotherapy [8] . With regards to MGMT methylation status and the occurrence of EGFR amplification, the group of glioblastoma that shows no hypermethylation with amplification constituted about 19% of cases and the same percentage was a group with hypermethylation and amplification. These patients could potentially benefit from bimodal chemotherapy with an alkylating agent and/or EGFR blocker additionaly [9] .
Mutations of the IDH1/IDH2 gene inversely correlated with glioma grade [3, 10] . IDH1/IDH2 mutations occurred mainly in secondary glioblastomas (> 70%), associated with young age of patients and with an increase in overall survival, but were very rare in primary glioblastomas (< 5%) [3] . IDH2 mutations are less frequent and prevail in anaplastic oligodendrogliomas (5%) and oligoastrocytomas (6%) [3] . 100% of patients with 1p/19q co-deletion had IDH1/IDH2 gene mutations and indicated occurrence of an oligodendroglial component in glioblastoma [11] .
LOH 1p was detected in up to 24% of glioblastomas [12] [13] [14] and the frequency of LOH 1p is similar in primary and secondary glioblastoma (12% and 15%, respectively) [15] , but its prognostic significance is not well established. It has been suggested that the isolated deletion of 1p may be associated with longer survival in high-grade gliomas composed of either pure astrocytic or mixed astrocytic-oligodendroglial phenotypes [16] . In one study, LOH 1p was found to be associated with longer survival in glioblastoma patients [17] ; however, another study reported no influence of isolated LOH 1p on survival [18] . LOH 19q (a common deletion at 19q13.3) frequency varies from 5% to 33% [12, 14, 18] and it is more frequent in secondary glioblastoma (54%) than in primary glioblastoma (6%) [15] . However, its impact on the prognosis in GB is not clear and remains controversial [14, 17, 19, 20] . Although the co-deletion LOH 1p/19q is an important predictive marker of chemosensitivity in oligodendrogliomas [5] , its occurrence is not frequent in primary GB [14, 18, 21] . The clinical significance of 1p/19q in glioblastoma is reported by some [4, 18] but another study showed no impact on the prognosis of GB [21] .
It was reported that LOH 10q is associated with shorter survival and poor clinical outcome [1, 2] , whereas other studies have found no such association [18, 22] . The frequency of LOH on chromosome 10 in primary and secondary GB is similar (47% in primary vs. 54% in secondary GB) but the differences concern the pattern of chromosomal loss [23] . The loss of an entire copy of chromosome 10 was usually observed in primary glioblastoma, while LOH is restricted to 10q in secondary glioblastoma [1, 23] .
Despite intensive investigations the molecular prognostic factors for primary glioblastoma are still debatable. The aim of our study was to evaluate the impact of LOH on chromosomes 1p, 19q, 9p, 10q, 13q, 17p either alone or by groups of LOH and TP53 mutations, and EGFR amplification on the survival of primary glioblastoma patients. We also focused on the occurrence and clinical significance of LOH 1p/19q in GB without an oligodendroglial component. [24] .
Material and methods
Patients with primary glioblastoma were selected on the basis of a short clinical history and the presence of histopathological features of glioblastoma without evidence of precursor low-grade astrocytomas at the first biopsy [25] . No oligodendroglial components were found in the histopathological study. According to the classical model of the molecular GB pathway, primary glioblastoma is characterized by high incidence of EGFR amplification (about 40%) and low frequency of IDH1 mutations (< 5%); additionally, TP53 mutations are less frequent in primary GB [26, 27] . To ascertain that the tumors studied were primary glioblastomas we used the following molecular criteria: frequencies of EGFR amplification (37.5%), IDH1 mutation (2.4%), and TP53 mutation (26.2%); the results were partly published before (EGFR amplification and TP53 mutations) [8] . Moreover, the 1p/19q co-deletion was infrequent (3 cases), and in 2 of these cases there was no co-presentation with IDH1 mutation (one of these cases was not determined for IDH1 mutation), which is typical for primary glioblastoma without an oligodendroglial component [11] (Table I) . It means that these cases showed molecular markers typical for primary GB. DNA was isolated by standard proteinase K digestion and phenol/chloroform extraction from frozen tumor tissue samples taken before radio-and/or chemotherapy, and from paired samples of peripheral blood leukocytes (WBC). Histological assessment of tissue fragments chosen for this study confirmed that all specimens consisted of at least 80% tumor cells.
Loss of heterozygosity analysis
Loss of heterozygosity analysis was performed using paired tumor specimens and corresponding peripheral blood samples. The LOH on chromosomes 1p, 9p, 10q, 13q, 17p, and 19q were examined using PCR with the markers D1S508 (approximate chromosomal localization 1p36.23), D9S156 (9p22), D9S162 (9p21-9p22), D10S587 (10q25-10q26), D10S536 (10q23), D13S256 (13q21-13q14), D17S675 (17p13.2) D19S206 (19q13.3), and D19S219 (19q13.3). Forward primers were fluorescence-labeled at the 5' end. The PCR was performed in thermocycling conditions established individually for each pair of primers. The PCR products were denatured and separated by gel electrophoresis in a LiCor automatic sequencer system for the analysis of PCR-generated alleles.
TP53 sequencing analysis
Four genomic regions of the TP53 gene (exons 5-8) were amplified by PCR, as described previously [8] . Sequence analysis was performed by the dideoxy termination method using the SequiTherm Excel DNA Sequencing Kit (Epicentre Technologies, Madison, WI) and commercially available fluorescent-labeled primers as described previously [8] . Products of the sequencing reaction were visualized and analyzed using a LiCor automated laser fluorescence sequencer.
IDH1 sequencing analysis
Exon 4, including codon 132 of the IDH1 gene, was amplified by PCR and sequenced using the dideoxy termination method and SequiTherm Excel DNA Sequencing Kit (Epicentre Technologies). The commercially available primers used for PCR amplification of the DNA sequences were: IDH1 -5'-GGCACC-CATCTTCTGTGTTT-3' (sense) and 5'-ATATATG-CATTTCTCAATTTCA-3' (antisense). The sequencing primers used were: IDH1 exon 4 -5'-CGGTCTTCA-GAGAAGCCATT-3' (sense) and IDH1 exon 4 -5'-CA-CATTATTGCCAACATGAC-3' (antisense). A Li-Cor automatic sequencer system was applied for the separation and analysis of PCR sequencing products.
EGFR amplification analysis
Multiplex PCR was performed for evaluation of EGFR amplification with superoxide dismutase 1 (SOD1) used as a reference gene as described previously [28] .
Statistical analysis
The Kaplan-Meier method was used to estimate overall survival, defined as the time from the date of the first surgery to the last observation. Differences in survival distributions were evaluated using a log-rank test. Univariate and multivariate survival analyses were performed using the Cox proportional hazard regression model. All results were considered statistically significant when two-sided p was < 0.05.
Results

Loss of heterozygosity
Loss of heterozygosity in at least one of the loci on all examined chromosomes was detected in 65% (26/40) of the informative cases. The results of LOH 
OS -overall survival, ms -months, ampl -amplification, ND -not done, NI -non-informative LOSS OF HETEROZYGOSITY IN PRIMARY GLIOBLASTOMAS
are shown in Table I and II. Representative results for LOH 1p and 19q analysis are shown in Fig. 1 .
Loss of heterozygosity and the influence on prognosis and age
The mean survival for the whole group of 42 patients was 12.9 ±8.5 months; median was 11.5 months (range 2-48). The correlations between LOH and survival are shown in Table III .
The clinical outcome of patients with LOH in at least one of the loci examined on all chromosomes, except LOH 13q (any LOH; n = 26), was significantly worse than that of patients without LOH (no LOH; n = 14) (log-rank, p = 0.007) (Fig. 2) . LOH 13q was excluded from this calculation because it was associated with a hazard ratio (HR) below 1.00, while all other LOHs were associated with HR > 1.00. The median overall survival of the patients with any LOH was 11 months (range 2-19 months), while median survival time was 13.0 months in the group of patients without LOH (range 6-48 months). Cox univariate analysis confirmed that patients with LOH at any of the loci examined was related to a significantly increased risk of death (hazard ratio 3.07; 95% CI: 1.29-7.31; p = 0.006). There was no statistically significant association between LOH 1p/19q and survival (hazard ratio 1.17; 95% CI: 0.36-3.8; p = 0.79). There was no statistically significant association between other LOH, as a single parameter, and overall survival (Table III) . The correlation between LOH (as a single parameter or a group of LOH) and age also was not statistically significant.
EGFR, TP53 and IDH1 alterations and the influence on prognosis and age
EGFR amplification was identified in 37.5% (15/40) . IDH1 mutation was found only in one case (2.4%) (case 25). In this case there was no 1p/19q codeletion. One case was not determined for IDH1 mutation. The TP53 mutations were identified in 26.2% (11/42) of cases within exons 5, 6, 7 and 8. All the mutations of TP53 were missense and are equally distributed through the exons (Table I) . There was no difference in survival between patients with these molecular alterations and patient age.
Discussion
The clinical outcome of glioblastoma patients with loss of heterozygosity on chromosomes 1p, 19q, 9p, 10q, 13q and 17p has been reported previously, but their prognostic influence in glioblastoma is still controversial [14, 18, [20] [21] [22] 29] . In this study LOH in at least one of the loci in all examined chromosomes was detected in 65% of cases. The presence of LOH at any of the loci examined (except LOH 13q) was related to a significant unfavorable impact on the overall survival of the patients (hazard ratio 3.07; 95% CI: 1.29-7.31; p = 0.006) (Table III) . In contrast, in a large GB study no correlation was found with survival for LOH 1p, 19q, LOH 9p or LOH 10q or other molecular alterations (EGFR amplification, CDK4 amplification, INK4A/ARF deletion) analyzed either alone or by groups of alterations [19] . We did not find any prognostic significance of LOH as a single parameter (Table III) . A shorter median survival in patients with LOH 10q had been reported previously [1] especially at the PTEN locus [22] . On the other hand, Houillier et al. found no correlation between LOH 10q and survival [19] , which was consistent with our study.
In our study the frequency of LOH10q was 38.5%. This frequency has been reported in approximately 36-76% of GB cases depending on the microsatellite markers used [1, 19, 22] . The 10q25, 10q23-24, 10p14-p15 and 10q23 regions were reported as most frequently deleted on chromosome 10 [1, 22] . The loci of several tumor suppressor genes have been identified on chromosome 10, i.e. PTEN/MMAC1 on 10q23.3 (satellite marker D10S1765) and suppressor gene DMBT1 (10q25.3-q26) [30, 31] . PTEN is a regulator of cell cycle, progression and apoptosis via the PI3K-AKT pathway, and is frequently lost in GB, mainly involved in late sequences of genetic alteration [32] . The LOH of the DMBT1 gene locus occurs in 21% to 79% of GB cases [22, 23] . Homozygous deletion of the DMBT1 gene was detected at a similar frequency (about 20%) in primary glioblastomas and secondary glioblastomas, suggesting that loss of DMBT1 is involved in the pathogenesis of both subtypes of glioblastoma and was significantly associated with shorter overall survival [33] . In this study, LOH 9p (locus on chromosome 9p21-22) was detected in 22.2% of cases. The CDKN2A (INK4A/ARF) genetic locus on chromosome 9p21 encodes two tumor suppressors: the p16INK4A cell cycle suppressor and p14 ARF [34, 35] , a regulator of TP53 stability. LOH 17p was detected in 14.3% and like TP53 mutation it has no impact on prognosis. In a previous study, poorer survival was associated significantly with the occurrence of either deletion of p16 (p = 0.031), LOH on 9p (p = 0.016), or LOH on 10q (p = 0.0007) in high-grade gliomas, but LOH 17p and TP53 mutation had no statistically significant effect on survival after adjustment for age [36] .
Loss of heterozygosity at 13q, which includes the RB1 gene, has been detected in 12% of primary glioblastomas [37] , which is similar to our results (10%). LOH 13q was excluded from the analysis because it was associated with a hazard ratio (HR) below 1.00, while all other LOHs were associated with HR > 1.00. We have not found in the literature data about the influence of LOH 13q on patient survival in GB.
In the present study, the frequencies of LOH 1p, LOH 19q and co-deletion of LOH 1p/19q were 17.9%, 25.6% and 7.14%, respectively. These results are consistent with other studies; the ranges of frequency of LOH 1p, 19q and LOH 1p/19q co-deletion were as follows: 0-24%, 5.3-33% and 0-13.3%, respectively [12, 18] .
Although the co-deletion LOH 1p/19q is an important diagnostic and prognostic marker of chemosensitivity in oligodendrogliomas [5] , its occurrence is not frequent in primary GB [12, 14, 18] and is mainly associated with the oligodendroglial component (GB-O). The frequency of GB-O in the whole group of glioblastomas has been observed in the range from 4.2% up to 27.2% [17, 21, 29, 38] . In GB-O cases, the frequency of LOH 1p was from 12 to 24%, 19q was from 32 to 43%, and combined 1p/19q was from 22 to 28% [39, 40] . In the more recent EORTC/NCIC trial study concerning a large group of 360 GB cases, an oligodendroglial component was found in 15% of all cases but co-deletion of 1p/19q was found in only one case [41] . Intriguingly, a more detailed study in GB-O using microdissection of tumor tissues with astrocytic and oligodendroglial components revealed no difference in the pattern of genetic alterations on chromosomes 1p and 19q in the same tumors [21] . In our study LOH 1p/19q co-deletion was infrequent and there was no co-presentation with IDH1 mutation, which is consistent with the histopathological lack of oligodendroglial component in these cases. Although the occurrence of 1p/19q loss has been associated with better prognosis in glioblastoma [4, 18] , another study showed no impact on the prognosis of GB, even within the oligodendroglial component (GB-O) [21] . In our study there was no influence of LOH 1p/19q co-deletion on overall patient survival.
Conclusions
Although the present study did not show any prognostic significance of LOH as a single parameter, the presence of LOH in at least one of the loci on all examined chromosomes (except LOH 13q) was related to a significant unfavorable impact on the overall survival of the patients.
We concluded that in primary glioblastoma a specific LOH group analysis may be important for the prognosis. In contrast to oligodendroglioma and secondary glioblastoma, 1p/19q co-deletion is rare in glioblastoma without an oligodendroglial component and does not influence glioblastoma patients' survival.
